Genomic landscape of hormone therapy-resistant HR-positive, HER2-negative breast cancer
Hormone therapy-resistant HR+/HER2-negative breast cancers are polyclonal, acquire actionable alterations at relapse, and moderate-depth ctDNA successfully identifies many clonal mutations, suggesting a role for liquid biopsy monitoring in these patients.
Authors
- Pallavi Parab (ORCID: https://orcid.org/0009-0005-3104-8079)
- Aishwarya Raja (ORCID: https://orcid.org/0000-0001-9060-0648)
- Nilesh Gardi
- Scott R. Sale
- Kunal Gala (ORCID: https://orcid.org/0000-0002-7794-8831)
- M. Sheshu Madhav (ORCID: https://orcid.org/0000-0001-6100-5751)
- Shalaka Prakash Joshi (ORCID: https://orcid.org/0000-0003-3813-4680)
- Rohan Chaubal (ORCID: https://orcid.org/0000-0002-7226-8757)
- Elizabeth Talker (ORCID: https://orcid.org/0000-0002-8274-1288)
- Rasika Kadam (ORCID: https://orcid.org/0009-0007-6570-8180)
- Tanuja M. Shet (ORCID: https://orcid.org/0000-0001-9294-9704)
- Suyash Sureshchandra Kulkarni (ORCID: https://orcid.org/0000-0001-5972-6111)
- Khushboo Gandhi (ORCID: https://orcid.org/0000-0002-7439-1417)
- Ankita Singh (ORCID: https://orcid.org/0000-0003-3505-1804)
- A. S. Kadam
- Seema Gulia (ORCID: https://orcid.org/0000-0001-5871-7395)
- Sudeep Gupta
- Nitin Shetty
- Jaya Chitra
- Rushikesh Mukhare
- Riddhi Ursekar
- Shwetali Pandey (ORCID: https://orcid.org/0000-0001-6446-1787)
Institutions
- Homi Bhabha National Institute (IN)
- Tata Memorial Hospital (IN)
- Advanced Centre for Treatment, Research and Education in Cancer (IN)
Publication Details
- Journal
- Breast Cancer Research and Treatment
- Published
- 2025-07-12
- DOI
- https://doi.org/10.1007/s10549-025-07759-7
- Citations
- 4
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 3.75